• Pre-announces Q2, EBITA SEK 14m vs. ABGSCe SEK 28m • Lower profitability in MBXP behind the miss •...
Redeye updates its estimates after reviewing Fantasma Games’ Q2 report, which showed lower growth th...
Ahead of Taaleri's Q2, we adjust our 2023 estimates to reflect the carry from Forest Fund III and ga...
Redeye initiates coverage of Lytix Biopharma, an immuno-oncology company with a Nobel Prize Laureate...
Suominen reported weaker than expected Q2 earnings but continues to anticipate stronger earnings in ...
Redeye provides an update after Gasprox’s Q2’23 report.
Planerar för ny datautläsning Ascelia meddelade under måndagskvällen att de planerar att genomföra e...
Sales and EBITA 2% and 14% vs. ABGSCeCustomer intake flat q-o-q (ABGSCe -2,500)Cons to lift '23e-'25...
Redeye shares its initial thoughts on FlexQube’s Q2 report, which was better than expected top-line-...
Suominen’s Q2 results showed some improvement in terms of operational efficiency, however top line f...
Redeye comments on Gasporox’s Q2’23 report, which was significantly stronger than expected on all it...
Redeye leaves a note following Alzinova's update regarding its Pre-IND meeting with the FDA.
Q2 EBITDA 16% below ABGSCe on higher costsFY'23 production guidance lowered by ~5%Fair value range r...
Q2 report due on Thursday, 17 AugustEBIT down on lowered marginsHopefully more clarity on strategy w...
The required revaluation of a certain number of patients showed a high level of variability and this...
NoHo reported Q2 EBIT 13% above Vara consensus, despite 4% lower sales.
Redeye comments on Maximum Entertainment (prev Zordix) ahead of its Q2-results (due 16 August) where...
Infrea redovisade minskad omsättning och resultat i Q2 påverkat av kallare väder.
Q2 EBITDA 16% below ABGSCe on higher opexReduces FY'23 production guidance by ~5%Negative estimate c...
NoHo Partners reported Q2 EBIT of EUR 10.7m, +13% versus Vara consensus and +9% versus our estimate.
